[go: up one dir, main page]

NO20045677L - Inhibitorer av JAK- og CDK2-proteinkinaser - Google Patents

Inhibitorer av JAK- og CDK2-proteinkinaser

Info

Publication number
NO20045677L
NO20045677L NO20045677A NO20045677A NO20045677L NO 20045677 L NO20045677 L NO 20045677L NO 20045677 A NO20045677 A NO 20045677A NO 20045677 A NO20045677 A NO 20045677A NO 20045677 L NO20045677 L NO 20045677L
Authority
NO
Norway
Prior art keywords
inhibitors
protein kinases
jak
compounds
cdk2 protein
Prior art date
Application number
NO20045677A
Other languages
English (en)
Other versions
NO20045677D0 (no
Inventor
Brian E Ledford
Original Assignee
Vertex Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharma filed Critical Vertex Pharma
Publication of NO20045677D0 publication Critical patent/NO20045677D0/no
Publication of NO20045677L publication Critical patent/NO20045677L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Materials For Medical Uses (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Foreliggende oppfinnelse tilveiebringer en forbindelse med formel I: eller et farmasøytisk akseptabelt salt derav. Disse forbindelser er inhibitorer av proteinkinaser, spesielt inhibitorer av mammalske JAK- og CDK2-proteinkinaser. Oppfinnelsen tilveiebringer også farmasøytisk akseptable sammensetninger omfattende forbindelsene ifølge oppfinnelsen og fremgangsmåter for å anvende disse forbindelser og sammensetninger ved behandling av en rekke proteinkinase-medierte forstyrrelser.
NO20045677A 2002-05-30 2004-12-28 Inhibitorer av JAK- og CDK2-proteinkinaser NO20045677L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38453802P 2002-05-30 2002-05-30
PCT/US2003/016900 WO2003101989A1 (en) 2002-05-30 2003-05-30 Inhibitors of jak and cdk2 protein kinases

Publications (2)

Publication Number Publication Date
NO20045677D0 NO20045677D0 (no) 2004-12-28
NO20045677L true NO20045677L (no) 2005-02-28

Family

ID=29712051

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20045677A NO20045677L (no) 2002-05-30 2004-12-28 Inhibitorer av JAK- og CDK2-proteinkinaser

Country Status (12)

Country Link
US (1) US7122552B2 (no)
EP (1) EP1507779A1 (no)
JP (2) JP2005528443A (no)
KR (1) KR20050013562A (no)
CN (1) CN1665810A (no)
AU (1) AU2003231880A1 (no)
CA (1) CA2487679A1 (no)
MX (1) MXPA04011956A (no)
NO (1) NO20045677L (no)
PL (1) PL374023A1 (no)
RU (1) RU2004138819A (no)
WO (1) WO2003101989A1 (no)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI329105B (en) * 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
MXPA05001096A (es) 2002-07-29 2005-11-23 Rigel Pharmaceuticals Inc Metodos para tratamiento o prevencion de enfermedades autoinmunes con compuestos de 2,4-diamino-pirimidina.
AU2004265288A1 (en) 2003-07-30 2005-02-24 Rigel Pharmaceuticals, Inc. 2,4-pyrimidinediamine compounds for use in the treatment or prevention of autoimmune diseases
SI1668014T1 (sl) 2003-09-17 2009-06-30 Janssen Pharmaceutica Nv Kondenzirane heterociklične spojine kot modulatorji serotoninskih receptorjev
AU2011253635B2 (en) * 2003-09-17 2014-10-30 Janssen Pharmaceutica, N.V. Fused heterocyclic compounds
US7473783B2 (en) 2003-12-17 2009-01-06 Sgx Pharmaceuticals, Inc. Bicyclic pyrazolo protein kinase modulators
WO2005123111A2 (en) * 2004-06-21 2005-12-29 Exelixis, Inc. Maxs as modifiers of the axin pathway and methods of use
RU2007110731A (ru) 2004-09-23 2008-10-27 Редди Юс Терапевтикс Новые соединения пиримидина, способ их получения и содержащие их композиции
CN101115761B (zh) 2005-01-19 2012-07-18 里格尔药品股份有限公司 2,4-嘧啶二胺化合物的前药及其应用
US20070203161A1 (en) 2006-02-24 2007-08-30 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
NZ563454A (en) 2005-06-08 2011-03-31 Rigel Pharmaceuticals Inc 2,4-diaminopyrimidine derivatives for inhibition of the JAK pathway
CA2642229C (en) 2006-02-24 2015-05-12 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
EP2012815A4 (en) * 2006-04-14 2009-12-09 Massachusetts Inst Technology IDENTIFICATION AND MODULATION OF MOLECULAR PATHS FOR PROCESSING NEURONAL PLASTICITY
CA2657227A1 (en) * 2006-07-14 2008-01-17 Novartis Ag Pyrimidine derivatives as alk-5 inhibitors
AU2007338574A1 (en) * 2006-11-01 2008-07-03 Vertex Pharmaceuticals Incorporated Tricyclic heteroaryl compounds useful as inhibitors of Janus kinase
CN101687863B (zh) * 2007-05-04 2012-09-12 阿斯利康(瑞典)有限公司 氨基-噻唑基-嘧啶衍生物及其治疗癌症的用途
LT2265607T (lt) * 2008-02-15 2017-03-27 Rigel Pharmaceuticals, Inc. Pirimidin-2-amino junginiai ir jų panaudojimas kaip jak kinazių slopiklių
AU2009244897B2 (en) 2008-04-16 2014-11-13 Alexion Pharmaceuticals, Inc. 2, 6-diamino- pyrimidin- 5-yl-carboxamides as syk or JAK kinases inhibitors
US8138339B2 (en) 2008-04-16 2012-03-20 Portola Pharmaceuticals, Inc. Inhibitors of protein kinases
EP2271631B1 (en) 2008-04-22 2018-07-04 Portola Pharmaceuticals, Inc. Inhibitors of protein kinases
WO2010060854A1 (en) * 2008-11-25 2010-06-03 Nerviano Medical Sciences S.R.L. Bicyclic pyrazole and isoxazole derivatives as antitumor and antineurodegenerative agents
WO2010093808A1 (en) * 2009-02-11 2010-08-19 Reaction Biology Corp. Selective kinase inhibitors
US8663210B2 (en) 2009-05-13 2014-03-04 Novian Health, Inc. Methods and apparatus for performing interstitial laser therapy and interstitial brachytherapy
JO3030B1 (ar) * 2009-06-26 2016-09-05 Galapagos Nv مركب جديد مفيد لمعالجة الامراض التنكسية والالتهابات
CN102471339A (zh) * 2009-07-15 2012-05-23 雅培制药有限公司 激酶的吡咯并吡啶抑制剂
CN106420756A (zh) * 2009-07-28 2017-02-22 里格尔药品股份有限公司 抑制jak途径的组合物和方法
EP2470541A1 (en) * 2009-08-28 2012-07-04 Array Biopharma, Inc. Raf inhibitor compounds and methods of use thereof
UY33213A (es) * 2010-02-18 2011-09-30 Almirall Sa Derivados de pirazol como inhibidores de jak
WO2012061428A2 (en) 2010-11-01 2012-05-10 Portola Pharmaceuticals, Inc. Nicotinamides as jak kinase modulators
US9198911B2 (en) 2010-11-02 2015-12-01 The Trustees Of Columbia University In The City Of New York Methods for treating hair loss disorders
JP6039683B2 (ja) 2011-11-23 2016-12-07 ポートラ ファーマシューティカルズ， インコーポレイテッド ピラジンキナーゼ阻害剤
WO2013113762A1 (en) 2012-01-31 2013-08-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and kits for predicting the risk of having a cutaneous melanoma in a subject
HRP20181976T1 (hr) * 2012-03-29 2019-01-25 The Trustees Of Columbia University In The City Of New York Postupci za liječenje poremećaja gubitka kose
RS61664B1 (sr) 2012-04-24 2021-04-29 Vertex Pharma Inhibitori dna-pk
WO2014013014A1 (en) 2012-07-18 2014-01-23 Fundació Privada Centre De Regulació Genòmica (Crg) Jak inhibitors for activation of epidermal stem cell populations
US9676756B2 (en) 2012-10-08 2017-06-13 Portola Pharmaceuticals, Inc. Substituted pyrimidinyl kinase inhibitors
HUE057527T2 (hu) 2013-03-12 2022-05-28 Vertex Pharma DNS-PK inhibitorok
HRP20181841T1 (hr) 2013-10-17 2019-01-11 Vertex Pharmaceuticals Incorporated Sukristali (s)-n-metil-8-(1-((2′-metil-[4,5′-bipirimidin]-6-il)amino)propan-2-il)kinolin-4-karboksamida i njegovih deuteriranih derivata kao inhibitora dna-pk
ES2702951T3 (es) * 2014-04-04 2019-03-06 Syros Pharmaceuticals Inc Inhibidores de quinasas dependientes de ciclina 7 (cdk7)
RU2742305C2 (ru) * 2014-12-30 2021-02-04 Новира Терапьютикс, Инк. Производные и способы лечения инфекций гепатита в
US10045981B2 (en) 2015-11-24 2018-08-14 Jakpharm, Llc Selective kinase inhibitors
WO2018041989A1 (en) 2016-09-02 2018-03-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for diagnosing and treating refractory celiac disease type 2
JP2019529475A (ja) 2016-09-27 2019-10-17 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ Ｄｎａ損傷剤とｄｎａ−ｐｋ阻害剤との組合せ物を使用する、がんを処置するための方法
US10759865B2 (en) 2017-08-22 2020-09-01 Eyal Levit Treatment of diabetes mellitus
WO2019046316A1 (en) * 2017-08-28 2019-03-07 Acurastem Inc. PIKFYVE KINASE INHIBITORS
CN108586341B (zh) * 2018-05-25 2020-05-08 天津商业大学 酰胺类化合物和其药用盐及其制备方法和药物用途
EP3942045A1 (en) 2019-03-21 2022-01-26 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
WO2020201362A2 (en) 2019-04-02 2020-10-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of predicting and preventing cancer in patients having premalignant lesions
WO2020212395A1 (en) 2019-04-16 2020-10-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of jak inhibitors for the treatment of painful conditions involving nav1.7 channels
KR20220098759A (ko) 2019-11-08 2022-07-12 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) 키나제 억제제에 대해 내성을 획득한 암의 치료 방법
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
CN114605390B (zh) * 2020-12-04 2024-08-16 上海凌达生物医药有限公司 具有cdk激酶抑制活性的化合物、其药物组合物和用途
JP2024519215A (ja) 2021-05-07 2024-05-09 カイメラ セラピューティクス， インコーポレイテッド Ｃｄｋ２分解剤およびそれらの使用
EP4526469A1 (en) 2022-05-16 2025-03-26 Institut National de la Santé et de la Recherche Médicale Methods for assessing the exhaustion of hematopoietic stems cells induced by chronic inflammation

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK27383A (da) * 1982-02-17 1983-08-18 Lepetit Spa Fremgangsmaade til fremstilling af pyrazol(4,3-c)pyridiner
GB0016877D0 (en) * 2000-07-11 2000-08-30 Astrazeneca Ab Chemical compounds

Also Published As

Publication number Publication date
WO2003101989A1 (en) 2003-12-11
EP1507779A1 (en) 2005-02-23
US20030236244A1 (en) 2003-12-25
JP2011006494A (ja) 2011-01-13
JP2005528443A (ja) 2005-09-22
NO20045677D0 (no) 2004-12-28
MXPA04011956A (es) 2005-03-31
US7122552B2 (en) 2006-10-17
KR20050013562A (ko) 2005-02-04
PL374023A1 (en) 2005-09-19
RU2004138819A (ru) 2005-06-10
CN1665810A (zh) 2005-09-07
AU2003231880A1 (en) 2003-12-19
CA2487679A1 (en) 2003-12-11

Similar Documents

Publication Publication Date Title
NO20045677L (no) Inhibitorer av JAK- og CDK2-proteinkinaser
DE60333387D1 (de) Triazolopyridazine als proteinkinase-inhibitoren
NO20051100L (no) Pyrazolsammensetninger anvendelige som GSK-3-inhibitorer
AU2003297160A1 (en) Benzisoxazole derivatives useful as inhibitors of protein kinases
NO20073140L (no) Pyrrolopyraziner og pyralopyraziner som er nyttige som inhibitorer av proteinkinaser
ATE371656T1 (de) Heteroaryl-pyrimidinderivate als jak-inhibitoren
DE60214703D1 (de) Thiazolverbindungen, die sich als inhibitoren von proteinkinasen eignen
NO20055496L (no) Pyrazolokinazolinderivater, metoder for deres fremstilling og deres anvendelse som kinaseinhibitorer
NO20071320L (no) Pyrazolsubstituerte aminoheteroarylforbindelser som protein kinase inhibitorer.
MXPA03010961A (es) Compuestos de tiazol utiles como inhibidores de proteinas cinasas.
NO20052888L (no) Diamintriazoler anvendelige som inhibitorer av proteinkinaser
MX2007014619A (es) Pirrolopiridinas de utilidad como inhibidores de proteina quinasa.
IL181987A0 (en) Diaminotriazole derivatives and pharmaceutical compositions containing the same
DE60332433D1 (de) Azolylaminoazine als proteinkinasehemmer
DE60332604D1 (de) Azolylaminoazine als proteinkinasehemmer
ATE365733T1 (de) Zusammensetzungen brauchbar als protein-kinase- inhibitoren
EP1485381B8 (en) Azolylaminoazine as inhibitors of protein kinases
TW200514776A (en) Aminotriazole compounds useful as inhibitors of protein kinases
NO20082026L (no) Deazapuriner som er nyttige som inhibitorer for Janus-kinaser
NO20025601L (no) Arylmetylaminderivater for anvendelse som tryptaseinhibitorer
NO20072567L (no) Triazoler nyttige som proteinkinase-inhibitorer
NO20082508L (no) Aminopyrimidiner anvendelige som kinaseinhibitorer
MXPA05009151A (es) Inhibidores de cinasa heterociclica.
MXPA04005809A (es) Inhibidores de proteinas quinasas.
WO2004072029A3 (en) Pyrazolopyridazines useful as inhibitors of protein kinases

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application